Traders sold shares of Express Scripts Holding Co. (NASDAQ:ESRX) on strength during trading hours on Wednesday. $36.00 million flowed into the stock on the tick-up and $60.64 million flowed out of the stock on the tick-down, for a money net flow of $24.64 million out of the stock. Of all stocks tracked, Express Scripts Holding had the 0th highest net out-flow for the day. Express Scripts Holding traded up $0.23 for the day and closed at $73.35

ESRX has been the topic of several analyst reports. Morgan Stanley downgraded Express Scripts Holding from an “equal weight” rating to an “underweight” rating and raised their target price for the company from $67.00 to $70.00 in a report on Monday, June 20th. Cowen and Company reiterated a “positive” rating and set a $83.00 target price on shares of Express Scripts Holding in a report on Wednesday, June 15th. Zacks Investment Research downgraded Express Scripts Holding from a “buy” rating to a “hold” rating in a report on Tuesday, July 19th. Bank of America Corp. reiterated a “neutral” rating and set a $82.00 target price on shares of Express Scripts Holding in a report on Tuesday, June 7th. Finally, Jefferies Group dropped their target price on Express Scripts Holding from $98.00 to $88.00 and set a “buy” rating on the stock in a report on Tuesday, July 26th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the company. Express Scripts Holding has a consensus rating of “Hold” and an average price target of $81.26.

The stock has a 50-day moving average price of $76.61 and a 200 day moving average price of $73.53. The firm has a market capitalization of $45.82 billion and a P/E ratio of 17.96.

Express Scripts Holding (NASDAQ:ESRX) last posted its quarterly earnings data on Monday, July 25th. The company reported $1.57 earnings per share for the quarter, hitting the consensus estimate of $1.57. During the same period in the prior year, the firm posted $1.44 EPS. The business had revenue of $25.20 billion for the quarter, compared to analyst estimates of $25.42 billion. Express Scripts Holding’s revenue for the quarter was down .9% on a year-over-year basis. Equities research analysts expect that Express Scripts Holding Co. will post $6.38 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of ESRX. Bbva Compass Bancshares Inc. boosted its position in Express Scripts Holding by 10.2% in the fourth quarter. Bbva Compass Bancshares Inc. now owns 76,215 shares of the company’s stock valued at $6,662,000 after buying an additional 7,083 shares during the period. Wafra Investment Advisory Group Inc. NY boosted its position in Express Scripts Holding by 975.2% in the fourth quarter. Wafra Investment Advisory Group Inc. NY now owns 165,049 shares of the company’s stock valued at $14,427,000 after buying an additional 149,699 shares during the period. Schwab Charles Investment Management Inc. boosted its position in Express Scripts Holding by 12.2% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 2,270,630 shares of the company’s stock valued at $198,476,000 after buying an additional 246,358 shares during the period. American International Group Inc. boosted its position in Express Scripts Holding by 2.6% in the fourth quarter. American International Group Inc. now owns 372,766 shares of the company’s stock valued at $32,583,000 after buying an additional 9,278 shares during the period. Finally, Airain ltd purchased a new position in Express Scripts Holding during the fourth quarter valued at approximately $4,009,000.

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.